Galantos Pharma is a drug development company focusing on new drugs for neurodegenerative diseases such as Alzheimer’s Dementia (AD).
The demand for effective and well-tolerated drugs for treatment and prevention of Alzheimer's disease is spiraling, as the world-wide incidence of this devastating disease is already at 35 million and will quadruple within the next 40 years. The costs to society have already reached 1% of the world's gross domestic product and will continue to rise. We see it as corporate mission to engage in AD drug development, and we do so by way of a dedicated team of chemists, neuropharmacologists and neurophysiologists, molecular and cell biologists. The main drug target is neuronal nicotinic acetylcholine receptors (nnAChR) of the human central nervous system. These receptors are known to become increasingly lost in AD, thereby impairing not only cholinergic but also glutamatergic, dopaminergic, serotonergic and GABAergic neurotransmission and leading to the cognitive and other behavioral deficits associated with this disease. Moreover, nicotinic receptors are also control elements of life and survival of neurons and their synaptic networks, and they are targets of ß-amyloid toxicity. All these properties make nicotinic receptors a most attractive target for development of mixed symptomatic and disease-modifying drug treatments for AD and other neurodegenerative diseases.
The lead structures of our drug candidates are mostly derived from pleiotropic, natural compounds, such as the plant alkaloid Galantamine. The founding team of Galantos Pharma has extensive knowledge in the chemistry, pharmacology and physiology of this drug and was instrumental in its development to market.
The most advanced drug candidate developed so far is a pro-drug of Galantamine, named Memogain®. Preclinical development has been completed and indicates the following medical benefits: (i) Significantly higher effectiveness as cognition enhancer, (ii) absence of dose-limiting gastro-intestinal adverse effects, (iii) faster and stronger onset of symptomatic efficacy, and (iv) significant slowing down of disease progression.